---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-016760"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2026-05-13T20:41:28+00:00"
generated_at: "2026-05-13T20:44:11.532125+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Reviva Q1 net loss $3.2M; stock moving from Nasdaq to OTCQB effective May 14

## Summary
- Net loss $3.2M ($0.46/share) vs $6.4M ($2.61) in Q1 2025; cash $22.2M up from $14.4M.
- Completed public equity offering raising $10M gross in March 2026.
- Filed provisional patent for new brilaroxazine form to extend exclusivity through 2046; FDA feedback expected mid-2026.
- RECOVER-2 Phase 3 schizophrenia trial enrollment planned for Q3 2026.
- Common stock to stop trading on Nasdaq and move to OTCQB on May 14, 2026, under symbol RVPH.

## SEC filing metadata
- accession: 0001437749-26-016760
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2026-05-13T20:41:28+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774926016760/0001437749-26-016760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774926016760/rvph20260513_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-016760
- JSON: https://secwatch.observer/filing/0001437749-26-016760.json
- Plain text: https://secwatch.observer/filing/0001437749-26-016760.txt

## Key facts
- Earnings Releases
  REVIVA PHARMACEUTICALS HOLDINGS, INC. reported first quarter ended March 31, 2026 results: net income net loss of approximately $3.2 million, or $0.46 per share, EPS $0.46 per share.
  - Period: first quarter ended March 31, 2026
  - Net income: net loss of approximately $3.2 million, or $0.46 per share
  - EPS: $0.46 per share
  - Result: reported results
  source text: Reviva Reports First Quarter 2026 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774926016760/0001437749-26-016760-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.